New publication in AJRCCM
Michael Combs and Robert Dickson have a new study in the Blue Journal: “The Lung Microbiome Predicts Mortality and Response to Azithromycin in Lung Transplant Patients with Chronic Rejection.”
In this study, we discovered that among lung transplant recipients with newly diagnosed rejection (Chronic Lung Allograft Dysfunction), lung microbiota predict mortality and differ among patients that do and don’t respond to azithromycin. Additionally, we find microbiome-associated differences in alveolar immunity across otherwise similar patients, and report a novel ex vivo approach to determine how differences in the alveolar microenvironment contribute to selective bacterial growth. Congrats to Michael!
Citation: Combs MP, Luth JE, Falkowski NR, Wheeler DS, Walker NM, Erb-Downward JR, Wakeam E, Sjoding MW, Dunlap DG, Admon AJ, Dickson RP, Lama VN. The Lung Microbiome Predicts Mortality and Response to Azithromycin in Lung Transplant Patients with Chronic Rejection. Am J Respir Crit Care Med. 2024 Jan 25. doi: 10.1164/rccm.202308-1326OC. PMID: 38271553.
Michael Combs